Thermally stable rotavirus vaccine formulations and methods of use thereof
The present invention relates to thermally stable oral rotavirus vaccine formulations comprising one or more rotavirus reassortant or attenuated rotavirus strains, a pharmaceutically acceptable calcium salt, adipic acid, sucrose, and sodium phosphate, wherein each of the one or more rotavirus reassortant or attenuated rotavirus strain is stable for 7 days at 37° C., for 45 days at 25° C. and for 2 years or more at 2-8° C. The calcium containing formulations of the invention may further comprise one or more excipients which are present in an amount that is effective to optimize the calcium ions free in solution to stabilize the rotavirus particles. In embodiments of the invention, the formulation comprises a surfactant, such as polysorbate 80. The invention also relates to methods of using the rotavirus vaccine compositions of the invention to prevent rotavirus infection, or to reduce the likelihood of infection or to prevent, ameliorate, or delay the onset or progression of the clinical manifestations thereof.
1. A liquid rotavirus vaccine formulation comprising a pharmaceutically effective amount of one or more rotavirus reassortants selected from the group consisting of: G1, G2, G3, G4, and P1A; about 3 mM of a pharmaceutically acceptable salt of calcium; about 1.5 M sucrose; about 465 mM adipic acid; and about 10 mM sodium phosphate; wherein the pH of the formulation is about 6.4 at 25° C.
2. The rotavirus vaccine formulation of claim 1 , wherein the calcium is from calcium chloride.
3. The rotavirus vaccine formulation of claim 1 , further comprising a non-ionic surfactant.
4. The rotavirus vaccine formulation of claim 3 , wherein the non-ionic surfactant is polysorbate 80, which is present in a concentration of 0.008% to 0.04% w/v.
5. The rotavirus vaccine formulation of claim 3 , wherein the non-ionic surfactant is polysorbate 80, which is present in a concentration of about 0.01% w/v.
6. The rotavirus vaccine formulation of claim 5 , wherein the formulation comprises G1, G2, G3, G4, and P1A rotavirus reassortants.
7. The rotavirus vaccine formulation of claim 5 , wherein the aggregate amount of rotavirus reassortants is from about 1.0×10 6 to about 50×10 6 infectious units per mL.
8. The rotavirus vaccine formulation according to claim 1 , further comprising tissue culture media.
9. The rotavirus vaccine formulation according to claim 8 , wherein the tissue culture media is present in an amount from about 2 to about 30% v/v.
10. The rotavirus vaccine formulation of claim 1 , wherein the formulation comprises:
a) G1, G2, G3, G4, and P1A rotavirus reasortants;
b) 1.5 M sucrose;
c) 465 mM adipic acid;
d) 10 mM sodium phosphate; and
e) 3 mM of a pharmaceutically acceptable salt of calcium.
11. The rotavirus vaccine formulation of claim 10 , further comprising 0.01% w/v of polysorbate 80.
12. The rotavirus vaccine formulation of claim 1 , wherein the formulation is thermally stable for at least 7 days at 37° C., at least 45 days at 25° C. and at least 2 years at 2-8° C.
13. A method of reducing the likelihood of rotavirus infection or for preventing or reducing the likelihood or severity rotavirus gastroenteritis in a child, comprising administering the formulation of claim 1 to the child orally.
14. The method of claim 13 , wherein the child is an infant between the ages of 6 and 12 weeks of age.
15. The method of claim 13 , further comprising the steps of: (a) waiting for a predetermined amount of time to pass; (b) administering an additional dose of the formulation to the child, and (c) optionally repeating steps (a) and (b) one or more times.
16. The method of claim 15 , wherein the method comprises administering the rotavirus vaccine formulation to the child in a 3-dose series, wherein the child is 32 weeks of age or younger at the completion of the series.
17. The method of claim 13 wherein the rotavirus vaccine formulation is concomitantly administered to the child with a second vaccine selected from the group consisting of: diphtheria and tetanus toxoids and acellular pertussis (DTaP), inactivated poliovirus vaccine (IPV), Haemophilus influenza type b conjugate (Hib), hepatitis B vaccine, and pneumococcal conjugate vaccine and combination thereof.